By Julie Steenhuysen CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good ...

Over my forty years or so in and around dealing rooms and financial markets, I have heard many theories as to how to approach that problem and have settled on a process that has worked for me ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

A March 11 email to FDA staff says the administration lowered government employee credit card limits to $1. Now to book ...

While JAZZ Pharmaceuticals JAZZ may not be a typical cannabis stock, it is the only company to market an FDA-approved drug ...

Many of the directions included in the order will be familiar to those who watched drug pricing policy closely during the ...

To get FDA approval, scientists must be able to demonstrate that a new drug or treatment is safe and effective. And currently, before they can test a new therapy in humans, they must show proof ...

The shares of Biocon Biologics Ltd were trading at ₹316.4 up by ₹10.15 or 3.31 per cent on the NSE today at 11 ... that the U.S. Food and Drug Administration has approved Jobevne (bevacizumab ...

Most of FDA reviewers are funded by industry fees, not taxpayer money. In fact, nearly half of the FDA’s $7 billion budget comes from fees paid by drug ... more than 15% of the agency ...